Signal, buried.
Thousands of trials, abstracts and filings land every month. The one move that changes your strategy is in there — you just can't surface it in time.
COMPETITIVE INTELLIGENCE · ONCOLOGY-ONLY
Oncology competitive intelligence, before the landscape moves.
Prognyx turns trials, readouts, deals and regulatory moves into one sourced answer for your asset and your next decision — delivered as a five-business-day pilot.
3,000+ trials watched
5 days scope-to-brief
1 focus — oncology
[ 01 ] THE PROBLEM
The field moves faster than any team can track.
Tools, not answers.
A six-figure database hands you data to mine. A consulting project hands you a deck — once. Neither watches your back on a Tuesday afternoon.
Priced for giants.
Enterprise intelligence is built for big-pharma budgets. The biotech with the most riding on a single asset is the one left flying blind.
3,000+
oncology trials in motion, watched to the primary record
5 days
business days from agreed scope to delivered brief
1
therapeutic focus — oncology, and nothing else
[ 02 ] WHAT PROGNYX DOES
Oncology competitive intelligence, focused on one decision.
Not a portal to mine or a six-week consulting project. One asset, one indication and one decision question — researched, sourced and delivered as a concise brief.
- Bounded. The question, evidence set and deadline are agreed before work starts.
- Sourced. Every claim traces back to the primary record — NCT, label, abstract, filing.
- Decision-ready. The so-what and the now-what, not a data dump.
- Tailored. Scoped to your assets, mechanisms and indications.
COMPETITIVE BRIEF
LIVE WATCH
KRAS G12C — second-line NSCLC
Competitor readoutESMO 2026
Threat levelElevated
Window to act~6 weeks
78
A rival's confirmatory data lands before your filing. Here's the angle, the risk to your positioning, and the three moves on the table.
SOURCED · ClinicalTrials.gov · ESMO abstract · FDA label
[ 03 ] HOW IT WORKS
From noise
to a decision,
in four moves.
Define
We map your competitive set — targets, mechanisms, indications and the assets that can move your value.
SCOPEWatch
We track trials, congress readouts, regulatory actions, deals and publications — straight to the primary source.
MONITORSynthesize
We turn it into what it means for you and what to do next — sharp, sourced, no filler.
ANALYZEDecide
You get briefs your team actually reads and forwards — plus answers on demand when the field shifts.
ACTThe next move,
first.
Scope the pilot→
[ 04 ] WHY PROGNYX
Not a database. Not a $150k deck. Your analyst.
Prognyx
Data platforms
Consulting
One defined decision scope
Tailored to your pipeline
Decision-ready (the so-what)
Oncology-deep
Days, not weeks
Accessible to a single-asset biotech
We don't out-database the giants. We out-matter them — on the one question they can't answer for you: what do I do about this, on my molecule, this week?
[ 05 ] FROM THE WATCHTOWER
Oncology intelligence, in the open.
CHMP backs J&J's teclistamab for earlier-line relapsed/refractory myeloma
Per J&J's release and OncLive, the EMA committee recommended TECVAYLI after just one prior therapy on 18 September 2026 — pushing the BCMA bispecific fight closer to…
Read briefing →
CancerNetwork: CHMP backed Lifyorli combo for platinum-resistant ovarian cancer
CancerNetwork and Corcept's wire release via STT Info report the glucocorticoid-receptor antagonist combo cleared the EMA's CHMP on 18 September 2026; the binding…
Read briefing →
Roche says Lunsumio combo hits PFS goal in Phase 3 CELESTIMO trial
Roche reports its Phase III CELESTIMO trial of mosunetuzumab plus lenalidomide beat rituximab plus lenalidomide on progression-free survival in relapsed/refractory…
Read briefing →
Pfizer withdraws EU bladder cancer filing for Zumrad after CHMP concerns, per AllSci
Trade press reports the CHMP-triggered retreat ended Zumrad's EU Joint Clinical Assessment; a later report frames it as Pfizer following AstraZeneca, a link Prognyx…
Read briefing →
Enhertu posts 14.3-month first-line PFS in HER2-mutant NSCLC (DESTINY-Lung04)
AstraZeneca reports a Phase III first-line PFS win over the immunotherapy-chemo standard; the hazard ratio and overall survival are not yet disclosed.
Read briefing →
Gotistobart lifts median OS in PRESERVE-003 stage 1 squamous NSCLC
BioNTech and OncoC4 reported 18.5-month median OS versus 10.0 months for docetaxel in non-pivotal stage 1 of PRESERVE-003; the pivotal stage 2 test is still the decision…
Read briefing →[ 06 ] THE OFFER
See the next move first.
Tell us the asset, indication and decision you need to clarify. We will confirm a written scope for a $2,000 one-off pilot, delivered in five business days.
How Prognyx knows this
Every claim is built from primary sources only — and traces back to a document you can open. No opinion you can't check.
Who's behind it
Rali Filali — founder of Prognyx · M.D. candidate. Independent — no platform or bank behind the read. Every brief is audited against the primary record before it reaches you. Competitive analysis of public information — not medical or investment advice.
$2,000 one-off pilot — one asset, one indication and one defined decision question, delivered in five business days with one written revision. See the exact scope
ONCOLOGY COMPETITIVE INTELLIGENCE · PROGNYX